Price Chart

Profile

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
URL https://www.plustherapeutics.com
Investor Relations URL http://ir.cytori.com/investor-relations/default.aspx
HQ State/Province Texas
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Jul. 22, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
URL https://www.plustherapeutics.com
Investor Relations URL http://ir.cytori.com/investor-relations/default.aspx
HQ State/Province Texas
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release N/A
Last Earnings Release Jul. 22, 2021
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A